Promising Results for B7-H3 Antibody-Drug Conjugate in Advanced Solid Tumors (including metastatic castration resistant prostate cancer)
/in Clinical Trial, Metastatic, Phase 1/by MaxAPVO442: A Promising New Bispecific Antibody for Prostate Cancer Treatment
/in Preclinical Research/by MaxMetformin Shows Promise in Reducing Side Effects of Hormone Therapy in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxJanux Therapeutics Announces 100% Response in Phase 1a Results for JANX007 in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxInhibition of SREBP Reinduces Docetaxel Sensitivity in Advanced Prostate Cancer
/in Preclinical Research/by MaxNewsletter 3
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Here I am with the third newsletter from the site. I have a hope: this week I found little new information about ongoing or starting clinical trials. I have a feeling that this might be because the “breaking news,” especially those that […]
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 50/2025 December 14, 2025
- GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial December 12, 2025
- MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors December 12, 2025
- Logic-gated DARPins, a Promising Advancement in Immune Therapy for Solid Tumors December 11, 2025
